Insulin resistance, a condition where cells fail to respond to insulin effectively, is a pressing health concern affecting millions worldwide. Associated with obesity, high blood pressure, and type 2 diabetes, its prevalence is alarmingly high, impacting over 11 million Canadians.

The conventional approach to insulin therapy often involves multiple daily injections, posing challenges for patients in terms of compliance and efficacy. Moreover, the current model fails to address the need for real-time insulin release over an extended period, leading to fluctuations in blood glucose levels and increased risk of complications.

To tackle this problem, we, Jelin Healthcare have come up with an approach to insulin delivery utilizing advanced nanoparticle technology. By encapsulating insulin in a biodegradable glucose-responsive polymeric matrix, we ensure precise and sustained release within the patient’s body.

Through a sophisticated microfluidic system, insulin-loaded nanoparticles are produced, offering a game-changing advantage for diabetic individuals. With just a single injection, patients can now maintain optimal glucose levels for up to 100 hours, eliminating the hassle of multiple daily injections and enhancing treatment adherence.

This innovative approach not only addresses the challenges of insulin resistance but also mitigates the risk of diabetic complications such as heart disease, stroke, kidney disease, and eye problems. By providing a seamless and efficient insulin delivery system, we aim to revolutionize diabetes management and improve the quality of life for millions worldwide.

The introduction of this insulin therapy marks a significant milestone in the field of diabetes care. By harnessing the power of nanoparticles and cutting-edge technology, we are paving the way for a brighter and healthier future for individuals living with insulin resistance and diabetes.

Insulin therapy reimagined. Say goodbye to multiple injections and hello to seamless glucose control with our nanoparticle solution.